{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:12Z","timestamp":1793083992735,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Biologics have emerged as an effective treatment of rheumatoid arthritis (RA). However, there is a significant proportion of patients who fail to respond to biologics. Identifying the predictors that affect the response to biologics remains challenging. A comprehensive literature search of PubMed, Embase, and Web of Science databases was conducted through May 1, 2022. We included all studies that used a multivariate model to assess for the predictors of remission in RA patients treated with biologics. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for risk factors reported in\u2009\u2265\u20093 studies using a random-effects model. A total of 16,934 patients with RA who were treated with biologics were included in twenty-one studies. Our study showed that old age (OR 0.98 (0.97, 0.99),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.00001), female gender (OR 0.66 (0.56, 0.77),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.00001), smoking history (OR 0.86 (0.75, 0.99),\n                    <jats:italic>P<\/jats:italic>\n                    0.04), obesity (OR 0.95 (0.91, 0.99),\n                    <jats:italic>P<\/jats:italic>\n                    0.02), poor functional status (OR 0.62 (0.48, 1.27),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.00001), high disease activity (OR 0.90 (0.85, 0.96),\n                    <jats:italic>P<\/jats:italic>\n                    0.0005), and elevated erythrocyte sedimentation rate (OR 0.99 (0.98, 1.00),\n                    <jats:italic>P<\/jats:italic>\n                    0.009) were poor predictors of remission. On the other hand, positive anti-citrullinated protein antibodies (OR 2.52 (1.53, 4.12),\n                    <jats:italic>P<\/jats:italic>\n                    0.0003) was associated with high remission rate. Old age, female gender, obesity, smoking history, poor functional status, high disease activity, and elevated ESR at the time of diagnosis have been associated with poor response to biologics. Our findings could help establish a risk stratification model for predicting the remission rate in RA patients receiving biologics.\n                  <\/jats:p>","DOI":"10.1007\/s10067-022-06307-8","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T17:02:21Z","timestamp":1660669341000},"page":"3615-3627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5711-8753","authenticated-orcid":false,"given":"Yasmin","family":"Khader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizullah","family":"Beran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ghazaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Lee-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam","family":"Altorok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"6307_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, M\u00fcller-Ladner U, Mysler EF, da Silva JAP, Po\u00f3r G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"6307_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"key":"6307_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, \u00d8stergaard M (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22\u201332. https:\/\/doi.org\/10.1002\/art.27227","journal-title":"Arthritis Rheum"},{"key":"6307_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","volume":"38","author":"C Yu","year":"2019","unstructured":"Yu C, Jin S, Wang Y, Jiang N, Wu C, Wang Q, Tian X, Li M, Zeng X (2019) Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol 38:727\u2013738. https:\/\/doi.org\/10.1007\/s10067-018-4340-7","journal-title":"Clin Rheumatol"},{"key":"6307_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6307_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"6307_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses Bmj 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"Measuring inconsistency in meta-analyses Bmj"},{"key":"6307_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"6307_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/s0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046\u20131055. https:\/\/doi.org\/10.1016\/s0895-4356(01)00377-8","journal-title":"J Clin Epidemiol"},{"key":"6307_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"6307_CR11","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558\u20131565. https:\/\/doi.org\/10.1093\/rheumatology\/kel149","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR12","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/ar1933","volume":"8","author":"J Listing","year":"2006","unstructured":"Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low\u2013results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66. https:\/\/doi.org\/10.1186\/ar1933","journal-title":"Arthritis Res Ther"},{"key":"6307_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.autrev.2009.01.005","volume":"8","author":"F Atzeni","year":"2009","unstructured":"Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P (2009) Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 8:431\u2013437. https:\/\/doi.org\/10.1016\/j.autrev.2009.01.005","journal-title":"Autoimmun Rev"},{"key":"6307_CR14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/rheumatology\/kes184","volume":"51","author":"H Canh\u00e3o","year":"2012","unstructured":"Canh\u00e3o H, Rodrigues AM, Mour\u00e3o AF, Martins F, Santos MJ, Canas-Silva J, Polido-Pereira J, Pereira Silva JA, Costa JA, Ara\u00fajo D, Silva C, Santos H, Duarte C, da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE, Solomon DH (2012) Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 51:2020\u20132026. https:\/\/doi.org\/10.1093\/rheumatology\/kes184","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jbspin.2013.04.005","volume":"81","author":"F Atzeni","year":"2014","unstructured":"Atzeni F, Bongiovanni S, Marchesoni A, Filippini M, Caporali R, Gorla R, Cavagna L, Favalli EG, Saccardo F, Sarzi-Puttini P (2014) Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. Joint Bone Spine 81:37\u201340. https:\/\/doi.org\/10.1016\/j.jbspin.2013.04.005","journal-title":"Joint Bone Spine"},{"key":"6307_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3899\/jrheum.131451","volume":"41","author":"C Barnabe","year":"2014","unstructured":"Barnabe C, Homik J, Barr SG, Martin L, Maksymowych WP (2014) The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. J Rheumatol 41:1607\u20131613. https:\/\/doi.org\/10.3899\/jrheum.131451","journal-title":"J Rheumatol"},{"key":"6307_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","volume":"43","author":"I Flouri","year":"2014","unstructured":"Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P (2014) Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 43:447\u2013457. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.07.011","journal-title":"Semin Arthritis Rheum"},{"key":"6307_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","volume":"53","author":"YM Pers","year":"2014","unstructured":"Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, Mercier G, Pallot Prades B, Wendling D, Gaudin P, Jorgensen C, Marotte H, Maillefert JF (2014) Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford) 53:76\u201384. https:\/\/doi.org\/10.1093\/rheumatology\/ket301","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000515","volume":"3","author":"C Nourisson","year":"2017","unstructured":"Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A (2017) Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the \u201cORA\u201d registry. RMD Open 3:e000515. https:\/\/doi.org\/10.1136\/rmdopen-2017-000515","journal-title":"RMD Open"},{"key":"6307_CR20","doi-asserted-by":"publisher","first-page":"6107217","DOI":"10.1155\/2019\/6107217","volume":"2019","author":"M Biggioggero","year":"2019","unstructured":"Biggioggero M, Mesina F, Favalli EG (2019) The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. Biomed Res Int 2019:6107217. https:\/\/doi.org\/10.1155\/2019\/6107217","journal-title":"Biomed Res Int"},{"key":"6307_CR21","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","volume":"58","author":"PDH Hamann","year":"2019","unstructured":"Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 58:2162\u20132169. https:\/\/doi.org\/10.1093\/rheumatology\/kez188","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/14397595.2018.1482609","volume":"29","author":"K Murakami","year":"2019","unstructured":"Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H (2019) Predictive factors for structural remission using abatacept: Results from the ABROAD study. Mod Rheumatol 29:406\u2013412. https:\/\/doi.org\/10.1080\/14397595.2018.1482609","journal-title":"Mod Rheumatol"},{"key":"6307_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/1756-185x.13511","volume":"22","author":"KC Wang","year":"2019","unstructured":"Wang KC, Liao HT, Chen WS, Lai CC, Chou CT, Chen MH, Tsai CY (2019) Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: a single-center experience in Taiwan. Int J Rheum Dis 22:860\u2013868. https:\/\/doi.org\/10.1111\/1756-185x.13511","journal-title":"Int J Rheum Dis"},{"key":"6307_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/acr2.11101","volume":"2","author":"JE Collins","year":"2020","unstructured":"Collins JE, Johansson FD, Gale S, Kim S, Shrestha S, Sontag D, Stratton J, Trinh H, Xu C, Losina E, Solomon DH (2020) Predicting remission among patients with rheumatoid arthritis starting tocilizumab monotherapy: model derivation and remission score development. ACR Open Rheumatol 2:65\u201373. https:\/\/doi.org\/10.1002\/acr2.11101","journal-title":"ACR Open Rheumatol"},{"key":"6307_CR25","doi-asserted-by":"publisher","first-page":"19717","DOI":"10.1038\/s41598-020-76842-4","volume":"10","author":"D Kida","year":"2020","unstructured":"Kida D, Takahashi N, Kaneko A, Hirano Y, Fujibayashi T, Kanayama Y, Hanabayashi M, Yabe Y, Takagi H, Oguchi T, Kato T, Funahashi K, Matsumoto T, Ando M, Kuwatsuka Y, Tanaka E, Yasuoka H, Kaneko Y, Hirata S, Murakami K, Sobue Y, Nishiume T, Suzuki M, Yokota Y, Terabe K, Asai S, Ishiguro N, Kojima T (2020) A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients. Sci Rep 10:19717. https:\/\/doi.org\/10.1038\/s41598-020-76842-4","journal-title":"Sci Rep"},{"key":"6307_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14397595.2019.1676369","volume":"30","author":"Y Nakashima","year":"2020","unstructured":"Nakashima Y, Kondo M, Shono E, Ishinishi T, Tsukamoto H, Kuroda K, Maeyama A, Harada H, Maekawa M, Shimauchi T, Nagamine R, Jojima H, Yoshizawa S, Tsuru T, Otsuka T, Miyahara H, Suematsu E, Wada K, Yoshizawa S, Inoue Y, Fukuda T, Ikemura S, Haraguchi A (2020) Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice. Mod Rheumatol 30:807\u2013815. https:\/\/doi.org\/10.1080\/14397595.2019.1676369","journal-title":"Mod Rheumatol"},{"key":"6307_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/1756-185x.13780","volume":"23","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T (2020) Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. Int J Rheum Dis 23:316\u2013324. https:\/\/doi.org\/10.1111\/1756-185x.13780","journal-title":"Int J Rheum Dis"},{"key":"6307_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14397595.2019.1702141","volume":"30","author":"A Yamaguchi","year":"2020","unstructured":"Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayamada S, Saito K, Tanaka Y (2020) 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Mod Rheumatol 30:799\u2013806. https:\/\/doi.org\/10.1080\/14397595.2019.1702141","journal-title":"Mod Rheumatol"},{"key":"6307_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14397595.2020.1795392","volume":"31","author":"SY Kawashiri","year":"2021","unstructured":"Kawashiri SY, Endo Y, Okamoto M, Tsuji S, Shimizu T, Sumiyoshi R, Koga T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kawakami A (2021) Contributing factors of clinical outcomes at 1 year post-diagnosis in early rheumatoid arthritis patients with tightly controlled disease activity in clinical practice: a retrospective study. Mod Rheumatol 31:343\u2013349. https:\/\/doi.org\/10.1080\/14397595.2020.1795392","journal-title":"Mod Rheumatol"},{"key":"6307_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","volume":"23","author":"K Murray","year":"2021","unstructured":"Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, Fearon U, Veale DJ (2021) Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther 23:25. https:\/\/doi.org\/10.1186\/s13075-020-02380-z","journal-title":"Arthritis Res Ther"},{"key":"6307_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/rheumatology\/keaa259","volume":"60","author":"A Rubbert-Roth","year":"2021","unstructured":"Rubbert-Roth A, Aletaha D, Devenport J, Sidiropoulos PN, Luder Y, Edwardes MD, Jacobs JWG (2021) Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology (Oxford) 60:682\u2013691. https:\/\/doi.org\/10.1093\/rheumatology\/keaa259","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3899\/jrheum.091432","volume":"37","author":"D Jawaheer","year":"2010","unstructured":"Jawaheer D, Maranian P, Park G, Lahiff M, Amjadi SS, Paulus HE (2010) Disease progression and treatment responses in a prospective DMARD-naive seropositive early rheumatoid arthritis cohort: does gender matter? J Rheumatol 37:2475\u20132485. https:\/\/doi.org\/10.3899\/jrheum.091432","journal-title":"J Rheumatol"},{"key":"6307_CR33","first-page":"1809","volume":"28","author":"S Kuiper","year":"2001","unstructured":"Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL (2001) Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. J Rheumatol 28:1809\u20131816","journal-title":"J Rheumatol"},{"key":"6307_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/ard.2006.056937","volume":"66","author":"K Forslind","year":"2007","unstructured":"Forslind K, Hafstr\u00f6m I, Ahlm\u00e9n M, Svensson B (2007) Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66:46\u201352. https:\/\/doi.org\/10.1136\/ard.2006.056937","journal-title":"Ann Rheum Dis"},{"key":"6307_CR35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3899\/jrheum.080724","volume":"36","author":"N Iikuni","year":"2009","unstructured":"Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, Tomatsu T, Kamatani N, Yamanaka H (2009) The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 36:508\u2013511. https:\/\/doi.org\/10.3899\/jrheum.080724","journal-title":"J Rheumatol"},{"key":"6307_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/rheumatology\/ket399","volume":"53","author":"RB Mueller","year":"2014","unstructured":"Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J (2014) Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford) 53:671\u2013677. https:\/\/doi.org\/10.1093\/rheumatology\/ket399","journal-title":"Rheumatology (Oxford)"},{"key":"6307_CR37","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/bph.14181","volume":"175","author":"V Francisco","year":"2018","unstructured":"Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F, G\u00f3mez R, Mobasheri A, Gualillo O (2018) Adipokines and inflammation: is it a question of weight? Br J Pharmacol 175:1569\u20131579. https:\/\/doi.org\/10.1111\/bph.14181","journal-title":"Br J Pharmacol"},{"key":"6307_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/br.41.1.205-216.1977","volume":"41","author":"PG Holt","year":"1977","unstructured":"Holt PG, Keast D (1977) Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol Rev 41:205\u2013216. https:\/\/doi.org\/10.1128\/br.41.1.205-216.1977","journal-title":"Bacteriol Rev"},{"key":"6307_CR39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nri803","volume":"2","author":"M Sopori","year":"2002","unstructured":"Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2:372\u2013377. https:\/\/doi.org\/10.1038\/nri803","journal-title":"Nat Rev Immunol"},{"key":"6307_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ncprheum0655","volume":"3","author":"M Harel-Meir","year":"2007","unstructured":"Harel-Meir M, Sherer Y, Shoenfeld Y (2007) Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 3:707\u2013715. https:\/\/doi.org\/10.1038\/ncprheum0655","journal-title":"Nat Clin Pract Rheumatol"},{"key":"6307_CR41","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::Aid-art5>3.0.Co;2-w","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131563. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9%3c1552::Aid-art5%3e3.0.Co;2-w","journal-title":"Arthritis Rheum"},{"key":"6307_CR42","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s11606-019-05230-0","volume":"34","author":"KE Donahue","year":"2019","unstructured":"Donahue KE, Schulman ER, Gartlehner G, Jonas BL, Coker-Schwimmer E, Patel SV, Weber RP, Bann CM, Viswanathan M (2019) Comparative effectiveness of combining MTX with biologic drug therapy versus either MTX or biologics alone for early rheumatoid arthritis in adults: a systematic review and network meta-analysis. J Gen Intern Med 34:2232\u20132245. https:\/\/doi.org\/10.1007\/s11606-019-05230-0","journal-title":"J Gen Intern Med"},{"key":"6307_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-018-1544-9","volume":"20","author":"J Bluett","year":"2018","unstructured":"Bluett J, Sergeant JC, MacGregor AJ, Chipping JR, Marshall T, Symmons DPM, Verstappen SMM (2018) Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Res Ther 20:50. https:\/\/doi.org\/10.1186\/s13075-018-1544-9","journal-title":"Arthritis Res Ther"},{"key":"6307_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70:755\u2013759. https:\/\/doi.org\/10.1136\/ard.2010.139725","journal-title":"Ann Rheum Dis"},{"key":"6307_CR45","doi-asserted-by":"publisher","unstructured":"Narv\u00e1ez J, Magallares B, D\u00edaz Torn\u00e9 C, Hern\u00e1ndez MV, Reina D, Corominas H, Sanmart\u00ed R, JM LL, Rodriguez de la Serna A, Nolla JM (2016) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 45:386-390. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.07.001","DOI":"10.1016\/j.semarthrit.2015.07.001"},{"key":"6307_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","volume":"75","author":"J Sokolove","year":"2016","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH (2016) Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis 75:709\u2013714. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207942","journal-title":"Ann Rheum Dis"},{"key":"6307_CR47","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.2174\/138161212802502161","volume":"18","author":"G Pongratz","year":"2012","unstructured":"Pongratz G, Fleck M (2012) Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs\u2013insights in pathomechanisms of autoimmunity. Curr Pharm Des 18:4526\u20134536. https:\/\/doi.org\/10.2174\/138161212802502161","journal-title":"Curr Pharm Des"},{"key":"6307_CR48","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/s0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389:2328\u20132337. https:\/\/doi.org\/10.1016\/s0140-6736(17)31472-1","journal-title":"Lancet"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06307-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06307-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T08:10:34Z","timestamp":1668154234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06307-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6307"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06307-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data is registered and publicly available at OSF registries. Data including the Review Manager file used for analysis, tables and figures summarizing the included studies, and the predictors that were extracted are all available at OSF registries.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data registration"}}]}}